Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of totally neoadjuvant FOLFOXIRI chemotherapy
(irinotecan, oxaliplatin and fluorouracil) followed by short-course radiation therapy and
XELOX chemotherapy in the patients with locally advanced rectal cancer.